Cell Culture Media Market Worth $14.64 Billion by 2029 - by Meticulous Research®

According to a new market research report, "Cell Culture Media Market by Product (Serum-free, Chemically Defined, Classical, Xeno-free/Animal Component Free), Application (Monoclonal Antibody, Diagnostics, Cancer and Stem Cell Research), End User (Pharma & Biotech, Academic)- Forecast to 2029", published by Meticulous Research®, the cell culture media market is expected to grow at a CAGR of 13.2% from 2022-2029 to reach $14.64 billion by 2029.

Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5318

Cell culture media, also known as growth media, is any gel or liquid created to support cellular growth in an artificial environment. When scientists remove cells, organs, or tissues from living creatures, they must keep them in an appropriate artificial environment. Cell culture media contains compounds required to support and regulate the growth of cells. These cells are used in the production of biopharmaceuticals or for research purposes. Growing demand for monoclonal bodies, rising funding for cell-based research, and increased R&D spending in the life science sector are some factors driving the cell culture media market.

COVID-19 Pandemic Impact: Cell Culture Media Market

During the pandemic, major pharmaceutical and biotech companies collaborated to find vaccines and treatment methods for containing the virus. The idea behind the collaboration was to come together and find a solution as quickly as possible during the pandemic. Collaborations also took place between companies and universities to speed up the research & production process. Outsourcing pharmaceutical and biotechnological research to contract research organizations (CROs) also increased during the pandemic. Below are some of the instances,

In 2022, GSK plc (U.K.) and Vir Biotechnology, Inc. (U.S.) announced the supply of Sotrovimab to the U.S. for the early treatment of COVID-19. Sotrovimab, a monoclonal antibody, was granted emergency use authorization (EUA) by the U.S. FDA in May 2021.
In May 2020, four CROs, which included Charnwood Molecular LTD (U.K.), Reach Separations (U.K.), XenoGesis (U.K.), and Aurelia Bioscience Ltd (U.K.), built a shared initiative to continue with their COVID-19 therapeutic research activity.
In April 2020, AstraZeneca plc (U.K.) and Oxford Biomedica plc (U.K.) announced an agreement for the global development and distribution of Oxford's potential recombinant adenovirus vaccine.
In March 2020, Eli Lilly and Company (U.S.) collaborated with AbCellera Biologics Inc. (Canada) on a COVID-19 antibody treatment. The two companies utilized AbCellera's rapid pandemic response platform to develop and manufacture therapeutic antibodies.
In March 2020, Mount Sinai Health System (U.S.) and Harbour BioMed (Hong Kong) signed a multi-year collaboration and utilized the H2L2 Harbour Mice platform to develop antibodies against the SARS-CoV-2.
Speak to our Analysts to Understand the Impact of COVID-19 on Your Business: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5318

The global cell culture media market is segmented based on product (serum-free media, chemically defined media, classical media, animal component-free media, and other cell culture media), application [bioproduction (monoclonal antibody production, therapeutic protein production, vaccine production, and cell & gene therapy)], diagnostics, cancer research, drug screening & development, and stem cell research), end user (pharmaceutical & biotechnology companies, academic & research institutes, and diagnostic laboratories) and geography. The study also evaluates industry competitors and analyzes the regional and country markets.

On the basis of product, in 2022, the serum-free media segment is estimated to account for the largest share of the cell culture media market. The major contributing factor for the large share of this segment is the higher use of cell culture techniques in companies and research institutes, which demand media to grow cells. Some of the major benefits offered by this media include reduced risk of serum borne agents and increase in cell culture productivity. Several serum-free media have been developed and are generally formulated to support the culture of a single cell type. The segment is also expected to grow at the highest CAGR during the forecast period.

On the basis of application, the bioproduction segment is expected to grow at the highest CAGR during the forecast period. The increased production of biotherapeutics for treating diseases like cancer, diabetes, rheumatoid arthritis, and other non-communicable diseases has created an unprecedented demand for cell culture media, which, in turn, is expected to drive the growth of this segment in the forecast period.

Based on the end user, the pharmaceutical & biotechnology companies segment is expected to grow at the highest CAGR during the forecast period. The major contributing factor is the increasing demand for antibody therapeutics and emerging biosimilars in the coming years.

Quick Buy - Cell Culture Media Market Research Report: https://www.meticulousresearch.com/Checkout/87099746

Geographically, North America is estimated to dominate the overall cell culture media market in 2022, followed by Europe and Asia-Pacific. Increased demand for cell-based diagnosis and treatments, the presence of major players, the availability of skilled professionals, and the presence of major research institutes are major contributing factors to the regional market's large share. However, Asia Pacific is expected to grow at the highest CAGR during the forecast period. The growth is attributed to the rising technological advancements in biotechnology & pharmaceutical centers, growing focus on developing vaccines & clinical research activities, the presence of major research organizations, low manufacturing & labor costs, and developing healthcare infrastructure.

The report also includes an extensive assessment of the product portfolio, geographic analysis, and key strategic developments adopted by leading market participants in the industry during 2019-2022. In recent years, the cell culture media market has witnessed several new product launches, partnerships, agreements and collaborations, expansions, and acquisitions. For instance, in January 2022, Cytiva (U.S.) signed an agreement with Nucleus Biologics, LLC (U.S.) to develop custom cell media for cell and gene therapies. Also, in November 2021, Sartorius AG (Germany) opened its Cell Culture Technology Center in Germany.

Some of the key players operating in this market are Merck KGaA (Germany), Thermo Fisher Scientific Inc. (U.S.), PromoCell GmbH (Germany), Cytiva (U.S.), Lonza Group Ltd (Switzerland), Corning Incorporated (U.S.), Becton, Dickinson and Company (U.S.), HiMedia Laboratories (India), Sartorius AG (Germany), FUJIFILM Holdings Corporation (Japan), Agilent Technologies, Inc. (U.S.), Miltenyi Biotec B.V. & Co. KG (Germany), BIOLOGOS (U.S.), STEMCELL Technologies Inc. (Canada), and Cell Applications, Inc. (U.S.).

To gain more insights into the market with a detailed table of content and figures, click here: https://www.meticulousresearch.com/product/cell-culture-media-market-5318

Scope of the Report:

Cell Culture Media Market, by Product

Serum-free Media
Chemically Defined Media
Classical Media
Animal Component Free Media
Other Cell Culture Media

Cell Culture Media Market, by Application

Bioproduction
Monoclonal Antibody Production
Therapeutic Protein Production
Vaccine Production
Cell and Gene therapy
Diagnostics
Cancer Research
Drug Screening and Development
Stem Cell Research

Cell Culture Media Market, by End User

Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Diagnostic Laboratories

About Us
We are the trusted research partners for leading businesses around the world, providing market intelligence focused towards building revenue transformation strategies. Our research is used by Fortune 500 organizations to attain success by scouting next generation revenue opportunities well ahead of their competition.

Address
Office No-202, 203,204,205,206
2nd Floor, Pushpak Business Hub,
Wakad, Pimpri-Chinchwad,
411057, India.

This release was published on openPR.